Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 173 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluzone®: Influenza Virus Vaccine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

NCT00258830
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®: Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

NCT00836953
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Pediatric formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 36 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 5, 2026, 6:19 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

NCT05518500
View directory record Official record
Conditions
Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Interventions
Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3), Flu Vaccine (Year 4)
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

NCT03617523
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 5, 2026, 6:19 PM EDT
Recruiting Phase 3 Interventional

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Weeks to 11 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influenza Vaccine Revaccination in Ambulatory Elderly Subjects

NCT00775450
View directory record Official record
Conditions
Influenza, Orthomyxovirus Infection, Myxovirus Infection
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
28
States / cities
Hoover, Alabama • Mobile, Alabama • Chandler, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

NCT01048879
View directory record Official record
Conditions
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions
pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 5, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

NCT00976027
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
9,172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
96
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gene Signatures of Influenza Vaccine Responses in Older Adults

NCT03603509
View directory record Official record
Conditions
Influenza
Interventions
Fluad Vaccine, Fluzone High-Dose
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

NCT02464163
View directory record Official record
Conditions
Influenza
Interventions
Panblok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Mobile, Alabama • DeLand, Florida • Savannah, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly

NCT01304771
View directory record Official record
Conditions
Influenza
Interventions
Synbiotic AKSB
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Revealing Protective Immunity to Influenza Using Systems Immunology

NCT06501963
View directory record Official record
Conditions
Influenza
Interventions
Live Attenuated Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine

NCT00283283
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 64 Years
Enrollment
1,316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

NCT01793883
View directory record Official record
Conditions
Influenza
Interventions
40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 64 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
70
States / cities
Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

NCT00380211
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
6
States / cities
Miami, Florida • Lenexa, Kansas • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

NCT00831987
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®: Influenza virus vaccine 2004-2005 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 5, 2026, 6:19 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

NCT03028987
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

NCT00385255
View directory record Official record
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Fluarix®, Boostrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
1,726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FLUAD® vs. Fluzone® High-Dose Study

NCT03183908
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Interventions
FLUAD®, Fluzone® High-Dose
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
757 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

NCT00694213
View directory record Official record
Conditions
Influenza
Interventions
VCL-IPM1, VCL-IPT1, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 5, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Chronic CMV Infection on Influenza Vaccine Responses

NCT02134184
View directory record Official record
Conditions
Cytomegalovirus Infections, Influenza
Interventions
Fluzone® 2012-2013 Formula NDC No 498281-012-50
Biological
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 5, 2026, 6:19 PM EDT